Gonadorelin is a synthetic decapeptide identical to the naturally occurring gonadotropin-releasing hormone (GnRH) produced in the hypothalamus. It stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which regulate testosterone production in men and ovulation in women. It is used clinically for diagnostic testing of pituitary function, and in pulsatile administration for certain infertility conditions. In the peptide community, it is commonly discussed as a complement to testosterone replacement therapy to maintain testicular function and fertility.
Category: Reproductive / Hormonal. Evidence rating: A (strong human clinical data).
Clinical status: FDA-approved (Factrel for diagnostic use; Lutrepulse for pulsatile infertility treatment, now discontinued). Generic diagnostic formulation available.
Gonadorelin binds to GnRH receptors on gonadotrope cells in the anterior pituitary gland, stimulating release of LH and FSH. When administered in a pulsatile fashion (mimicking natural hypothalamic GnRH secretion every 60–120 minutes), it maintains or restores the physiological LH/FSH surge needed…
Research base: 549 registered clinical trials and 39 indexed publications reference Gonadorelin.
Safety considerations: Common: headache, flushing, nausea, dizziness, injection site reactions; Rare: facial/lip/tongue/throat swelling (allergic reaction); Injection site hardening with repeated SC administration.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
Related peptides: Kisspeptin, Oxytocin, Vasopressin.
Compare: Gonadorelin vs Kisspeptin, Gonadorelin vs Oxytocin, Gonadorelin vs Vasopressin.
Gonadorelin stimulates your pituitary to produce LH naturally, while HCG mimics LH directly. Gonadorelin works "upstream" — it preserves the full hypothalamic-pituitary-gonadal axis. HCG bypasses the pituitary entirely. Both can maintain testicular function during TRT.
After the FDA reclassified HCG as a biologic in 2020, compounding pharmacies could no longer easily produce it. Some TRT clinics switched to gonadorelin as an alternative to maintain fertility and testicular size during testosterone therapy.
Pulsatile administration (every 60–120 min) increases LH/FSH and thus testosterone. But continuous (non-pulsatile) administration paradoxically suppresses LH/FSH by downregulating GnRH receptors — this is the same mechanism used in prostate cancer treatment with GnRH agonists.